PGGM Investments Purchases 60,384 Shares of Illumina, Inc. (NASDAQ:ILMN)

PGGM Investments lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 39.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 211,834 shares of the life sciences company’s stock after buying an additional 60,384 shares during the quarter. PGGM Investments’ holdings in Illumina were worth $29,496,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ILMN. Vanguard Group Inc. boosted its position in Illumina by 15.0% during the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Barclays PLC boosted its position in Illumina by 120.0% during the third quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after purchasing an additional 964,709 shares in the last quarter. abrdn plc boosted its position in Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after purchasing an additional 299,827 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Illumina by 245.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock valued at $57,366,000 after purchasing an additional 296,990 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Illumina by 6.6% during the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after purchasing an additional 225,074 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN stock traded up $1.23 during trading on Friday, hitting $122.28. 829,331 shares of the company traded hands, compared to its average volume of 1,470,247. The stock’s 50-day simple moving average is $131.51 and its 200 day simple moving average is $127.39. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $19.47 billion, a PE ratio of -16.66 and a beta of 1.19. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $213.91.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. Illumina’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $0.14 earnings per share. On average, equities analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on ILMN. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. Finally, TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.